Prognostic urinary biomarkers for bladder cancer | Download Table
Cells | Free Full-Text | Emerging Roles of Cancer Stem Cells in Bladder Cancer Progression, Tumorigenesis, and Resistance to Chemotherapy: A Potential Therapeutic Target for Bladder Cancer
Bladder Cancer Biomarkers | Encyclopedia MDPI
Diagnostics | Free Full-Text | Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review
Tumor immune microenvironment-based classifications of bladder cancer for enhancing the response rate of immunotherapy: Molecular Therapy - Oncolytics
Urinary biomarkers to mitigate diagnostic delay in bladder cancer during the COVID-19 era | Nature Reviews Urology
Gender-specific Differences in Recurrence of Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis - European Urology Focus
Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study - eBioMedicine
Non muscle invasive bladder cancer treatment - WCRJ
Bladder Cancer Survival: The Importance of Early Detection | Cxbladder
Tumor Markers - Priority Health
Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer | Scientific Reports
Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective | Nature Reviews Urology
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study - The Lancet Oncology
Summary of urinary markers for bladder cancer | Download Table
ABYNTEK | Tumor markers for cancer research: FAQS
Recurrent ZNF83-E293V Mutation Promotes Bladder Cancer Progression through the NF-κB Pathway via Transcriptional Dysregulation of S100A8: Molecular Therapy
Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non–muscle-invasive bladder cancer and with low and intermediate EORTC-risk score | PLOS ONE
Frontiers | Detecting and monitoring bladder cancer with exfoliated cells in urine
Diagnosis of Bladder Cancer Recurrence Based on Urinary Levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 Hypermethylation | PLOS ONE
Bladder Cancer Markers and Recent Innovations | IntechOpen
![PDF] Tumor Markers of Breast Cancer: Role in Early Diagnosis, Monitoring Response to Therapy and Determination of Prognosis | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/54ce5e0004d854229da124b4ed00755e2e2df55b/6-Table1-1.png "PDF] Tumor Markers of Breast Cancer: Role in Early Diagnosis, Monitoring Response to Therapy and Determination of Prognosis | Semantic Scholar")
PDF] Tumor Markers of Breast Cancer: Role in Early Diagnosis, Monitoring Response to Therapy and Determination of Prognosis | Semantic Scholar
Urinary peptide panel for prognostic assessment of bladder cancer relapse | Scientific Reports
Cepheid | Bladder Cancer Monitor Biomarker Test - Xpert Bladder Cancer Monitor
Unmet Clinical Needs and Future Perspectives in Non–muscle-invasive Bladder Cancer - European Urology Focus
Useful and potentially useful urine markers for bladder cancer. | Download Table
